ePrints

Practical aspects of using botulinum toxin type B

Lookup NU author(s): Professor Michael Barnes

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Elan's botulinum toxin type B (NeuroBloc((R))/MYOBLOC (TM)) has several potential advantages over the currently available type A toxins. These include a solution to the problems of treating patients with poor responsiveness to the type A toxins (including those patients who have developed secondary non-responsiveness), and may include a more favourable safety profile and a relative lack of spread of paralytic effects from injected to non-injected muscles (which may reduce unwanted muscle weakness). As the new type B toxin will be supplied in liquid form, reconstitution in the clinic is avoided, potentially resulting in important time and cost benefits. These may be augmented by a duration of effect, approximately 12-16 weeks, that may be longer than that associated with the type A toxins.

Publication metadata

Author(s): Barnes MP

Publication type: Editorial

Publication status: Published

Journal: European Journal of Neurology

Year: 2001

Volume: 8

Issue: s4

Pages: 19-21

ISSN (print): 1351-5101

ISSN (electronic): 1468-1331

Publisher: Wiley-Blackwell Publishing Ltd.

URL: http://dx.doi.org/10.1046/j.1468-1331.2001.00005.x

DOI: 10.1046/j.1468-1331.2001.00005.x

Share